Pegcetacoplan: A New Opportunity for Complement Inhibition in PNH

被引：9
|
作者：
Weitz, Ilene Ceil [1 ]
机构：
[1] Keck USC Sch Med, Jane Anne Nohl Div Hematol, Los Angeles, CA 90089 USA
来源：
JOURNAL OF BLOOD MEDICINE | 2023年 / 14卷
关键词：
PNH; complement inhibition; extravascular hemolysis; PAROXYSMAL-NOCTURNAL HEMOGLOBINURIA; ECULIZUMAB; HEMOLYSIS;
D O I：
10.2147/JBM.S362220
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
Pegcetacoplan is the newest inhibitor of the complement system to be approved by the FDA and EMA for the treatment of Paroxysmal Nocturnal Hemoglobinuria (PNH). The cyclic peptide inhibitor of C3 was evaluated in several clinical trials in PHN leading to its approval. The focus of this paper will review the efficacy and safety of Pegcetacoplan (PEG), and considerations for use in patients with PNH.
引用
收藏
页码：239 / 245
页数：7
相关论文
共 50 条
  • [31] Moving toward Individual Treatment Goals with Pegcetacoplan in Patients with PNH and Impaired Bone Marrow Function
    Szer, Jeff
    Panse, Jens
    Kulasekararaj, Austin
    Oliver, Monika
    Fattizzo, Bruno
    Nishimura, Jun-ichi
    Horneff, Regina
    Szamosi, Johan
    de Latour, Regis Peffault
    INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2024, 25 (16)
  • [32] COMPLEMENT INHIBITION - IS THIS A NEW THERAPEUTIC MODALITY
    PORCEL, JM
    MEDICINA CLINICA, 1995, 105 (18): : 700 - 702
  • [33] Pegcetacoplan (Syfovre™): targeting complement C3 in geographic atrophy
    Mastellos, Dimitrios C.
    Lambris, John D.
    TRENDS IN PHARMACOLOGICAL SCIENCES, 2024, 45 (12) : 1175 - 1176
  • [34] PNH: new options
    Hill, A.
    LEUKEMIA RESEARCH, 2009, 33 : S20 - S21
  • [35] Complement inhibition: a new strategy of antiphlogistic therapy
    Kirschfink, M
    10TH INTERNATIONAL CONGRESS ON IMMUNOLOGY, VOLS 1 AND 2, 1998, : 1343 - 1349
  • [36] NEW ASPECTS OF ANTITHROMBOTICS - INHIBITION OF COMPLEMENT ACTIVATION
    Kalbitz, Miriam
    Umme, A.
    Rittirsch, D.
    Brueckner, U. B.
    Gebhard, F.
    Huber-Lang, M.
    SHOCK, 2009, 32 : 4 - 4
  • [37] Characterizing New-Onset Exudation in the Randomized Phase 2 FILLY Trial of Complement Inhibitor Pegcetacoplan for Geographic Atrophy
    Wykoff, Charles C.
    Rosenfeld, Philip J.
    Waheed, Nadia K.
    Singh, Rishi P.
    Ronca, Nick
    Slakter, Jason S.
    Staurenghi, Giovanni
    Mones, Jordi
    Baumal, Caroline R.
    Saroj, Namrata
    Metlapally, Ravi
    Ribeiro, Ramiro
    OPHTHALMOLOGY, 2021, 128 (09) : 1325 - 1336
  • [38] The inhibition of several components of terminal complement pathway results in C3 binding to PNH red blood cells
    Sica, Michela
    Notaro, Rosario
    AMERICAN JOURNAL OF HEMATOLOGY, 2024, 99 (03) : 505 - 507
  • [39] Complement activation and opsonization of PNH erythrocytes in patients treated with eculizumab
    Subias Hidalgo, Marta
    Lopez, Alicia
    Anter, Jaouad
    Pinto Garcia, Sheila
    Ataulfo Gonzalez-Fernandez, Fernando
    Villegas-Martinez, Ana
    Ojeda, Emilio
    Rodriguez de Cordoba, Santiago
    MOLECULAR IMMUNOLOGY, 2015, 67 (01) : 185 - 185
  • [40] Microvesicles generated from PNH red blood cells by complement activation contribute to the thrombotic diathesis in PNH.
    Ninomiya, H
    Kawashima, Y
    Hasegawa, Y
    Nagasawa, T
    BLOOD, 1998, 92 (10) : 155A - 155A
12345